MedTrace Logo

Effect of Banning Menthol Flavorant on Cigarette and E-Cigarette Use

NCT03402243 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 47

Last updated 2021-08-10

Study results available
· View outcomes & findings →

Summary

In this pilot study, menthol cigarette smokers will be randomized to one of three experimental marketplaces: 1) a condition simulating a ban on menthol cigarettes but not menthol e-cigarettes (condition A); 2) a condition simulating a ban on both menthol cigarettes and menthol e-cigarettes (Condition B); and 3) a condition in which menthol is not banned for either product (Condition C - the control condition). All conditions would have medicinal nicotine available if subjects decide to quit tobacco products entirely. At visits occurring every two weeks over a 6 week period, subjects will receive "credits" that they could exchange for any product available in their randomized marketplace condition. Outcomes include the amount of each tobacco product used.

Conditions

  • Tobacco Use Disorder

Interventions

OTHER

Menthol ban on cigarettes

Participants will have menthol and tobacco flavored e-cigarettes available but only non-menthol cigarettes

OTHER

Menthol ban on cigarettes and e-cigarettes

Participants will have neither menthol flavored cigarettes or e-cigarettes available

OTHER

No menthol ban

Participant will have menthol and tobacco flavored cigarettes and e-cigarettes available

Sponsors & Collaborators

Study Design

Allocation
RANDOMIZED
Purpose
OTHER
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
64 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2018-02-26
Primary Completion
2020-03-25
Completion
2020-03-25

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03402243 on ClinicalTrials.gov